Open AccessCanagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy
Author(s) -
Zhipeng Xu,
Wenxin Hu,
Bin Wang,
Ting Xu,
Jianning Wang,
Dan Wei
Publication year - 2022
Publication title -
yonsei medical journal/yonsei medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.702
H-Index - 63
eISSN - 1976-2437
pISSN - 0513-5796
DOI - 10.3349/ymj.2022.63.7.619
Subject(s) - canagliflozin , nonalcoholic fatty liver disease , endocrinology , medicine , lipid metabolism , lipogenesis , type 2 diabetes , fatty liver , diabetes mellitus , disease
Nonalcoholic fatty liver disease (NAFLD) is closely associated with metabolic diseases, including obesity and diabetes, and has gradually become the most common cause of chronic liver disease. We investigated the effects of sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin on NAFLD in high-fat diet (HFD)-induced obese mice and possible underlying mechanisms.